Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796548 | 0.83 | MCL1 (0.53) | MCL1PPARGGAAL3MBTL1ALDH1A1 | |
| Hydroxyamine SCHEMBL5793019 | 0.82 | MCL1 (0.51) | MCL1PPARGGAAL3MBTL1ALDH1A1 | |
| SCHEMBL5744163 | 0.80 | MCL1 (0.52) | MCL1PPARGGAACA9L3MBTL1 | |
| SCHEMBL5745194 | 0.79 | MCL1 (0.50) | MCL1PPARGGAAHSD17B3KMT2A | |
| SCHEMBL5798276 | 0.79 | MCL1 (0.50) | MCL1PPARGGAACA9L3MBTL1 | |
| SCHEMBL6882621 | 0.78 | HSD17B3 (0.50) | MCL1PPARGGAAHSD17B3ALDH1A1 | |
| SCHEMBL12997375 | 0.78 | MCL1 (0.61) | MCL1PPARGGAAL3MBTL1POLB | |
| SCHEMBL6074714 | 0.76 | MCL1 (0.52) | MCL1PPARGL3MBTL1POLBMEN1 | |
| SCHEMBL5745589 | 0.76 | MCL1 (0.47) | MCL1PPARGGAAL3MBTL1HSD17B3 | |
| SCHEMBL6887925 | 0.75 | MCL1 (0.46) | MCL1PPARGGAACA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | DDC, ODC1, DDT | MCL1 2711/4885PPARG 3668/4885GAA 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.